VEGFR2 inhibition was effective in vessel-rich cancer types (renal cell carcinoma, ovarian cancer, hepatocellular carcinoma), but not in vessel-poor cancer types (colorectal cancer, pancreatic cancer) [40]. This evidence concerns the gene KDR and cancer.